𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rationale for the treatment of non-small cell lung cancer

Book ID
122041491
Publisher
Elsevier Science
Year
1994
Tongue
English
Weight
160 KB
Volume
11
Category
Article
ISSN
0169-5002

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Treatment Rationale Study Design for the
Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer
✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We πŸ“‚ Article πŸ“… 2012 πŸ› CIG Media Group, LP. 🌐 English βš– 255 KB
Treatment Rationale and Study Design for
Treatment Rationale and Study Design for the PointBreak Study: A Randomized, Open-label Phase III Study of Pemetrexed/Carboplatin/Bevacizumab Followed by Maintenance Pemetrexed/Bevacizumab Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer
✍ Jyoti D. Patel; Philip Bonomi; Mark A. Socinski; Ramaswamy Govindan; Shengyan Ho πŸ“‚ Article πŸ“… 2009 πŸ› CIG Media Group, LP. 🌐 English βš– 100 KB